Factor XI inhibitor - Bayer HealthCare
Alternative Names: FXI inhibitorLatest Information Update: 28 May 2022
At a glance
- Originator Bayer HealthCare
- Class Antihaemorrhagics; Antithrombotics; Blood coagulation factors; Coagulants
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Thrombosis in Germany
- 01 Apr 2019 Phase-I development in Thrombosis is ongoing in Germany (Bayer pipeline, April 2019)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Thrombosis in Germany